Mallinckrodt makes $1.33 billion buy of Therakos

In its second major acquisition of the year, Mallinckrodt Plc agreed to purchase immunotherapy company Therakos, Inc. for $1.33 billion. The purchase follows Mallinckrodt’s deal for respiratory drug maker Ikaria, Inc. in March for $2.3 billion.

By buying Therakos, the St. Louis-headquartered pharmaceutical company gets access to Therakos’s therapeutic platform, currently the world’s only approved, fully integrated system of its kind.

Read more from the St. Louis Post-Dispatch


Tags:, , , , ,

Leave a Reply